Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients by Jäger, R et al.
Serum levels of the angiogenic factor pleiotrophin in relation to
disease stage in lung cancer patients
RJ a ¨ger*
1, B List
1, C Knabbe
3, B Souttou
5, D Raulais
6, T Zeiler
2, A Wellstein
4, A Aigner
7, A Neubauer
1 and
G Zugmaier*
1
1Philipps University of Marburg, Center of Internal Medicine, Department Hematology/Oncology Baldingerstr., 35033 Marburg, Germany;
2Philipps University of
Marburg, Department Transfusion Medicine and Haemostaseology, Baldingerstr., Marburg, Germany;
3Robert-Bosch-Krankenhaus, Department Clinical
Pathology, Stuttgart, Germany;
4Georgetown University, Lombardi Cancer Center, Reservoir Road, Washington, D.C., USA;
5Institute d ￿Oncologie Cellulaire
et Moleculaire Humaine, Bobigny, France;
6Differentiation and Cell Proliferation, INSERM, U440, 75005 Paris, France;
7Philipps University of Marburg,
Department Pharmacology, Max v. Frisch Str., Marburg Germany
Pleiotrophin is a heparin-binding growth factor involved in the differentiation and proliferation of neuronal tissue during
embryogenesis, and also secreted by melanoma and breast carcinoma cells. Pleiotrophin exhibits mitogenic and
angiogenic properties and has been shown to inﬂuence the vascular supply, expansion and metastasis of tumour cells.
Our aim was to study the serum and plasma concentrations of pleiotrophin and the classical angiogenic growth factor
vascular endothelial growth factor. Using a speciﬁc ELISA-test we studied patients with small cell lung cancer (n=63),
and patients with non-small cell lung cancer (n=22) in comparison to healthy control subjects (n=41). In most of the
lung cancer patients (81%), we found serum levels of pleiotrophin above those of control subjects (P50.001). Of the
63 small cell lung cancer patients in the study pleiotrophin serum levels were elevated in 55 cases (87%) and in 14
cases (63%) of the 22 non-small cell lung cancer patients. Pleiotrophin mean serum concentrations were 10.8-fold higher
in the tumour patient group as compared to the control group (P50.001). Furthermore, pleiotrophin serum levels
correlated positively with the stage of disease and inversely with the response to therapy. Plasma vascular endothelial
growth factor concentrations were elevated in only in 28.6% of small cell lung cancer and 45.5% of non-small cell lung
cancer patients by an average of 2.3-fold. Quite strikingly, there was no apparent correlation between the plasma
vascular endothelial growth factor concentration and the stage of disease. Our study suggests that pleiotrophin may be
an early indicator of lung cancer and might be of use in monitoring the efﬁcacy of therapy, which needs to be
conﬁrmed by larger studies.
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The development of a neovascular network, a process known
as angiogenesis, has been shown to be important in the
growth of a variety of human solid tumours, including lung
cancer. Angiogenic factors, produced either by tumour cells
or by non-tumour cells within the tumour microenvironment,
act in concert with angiogenesis inhibitors to regulate the
process of tumour neo-vascularisation. A number of factors
which promote the migration of vascular endothelial cells have
been identiﬁed and include pleiotrophin (PTN) and vascular
endothelial growth factor (VEGF) (Connolly et al, 1989; Fang
et al, 1992; Zhang and Deuel, 1999; Kuroi and Toi, 2001;
Souttou et al, 2001).
Vascular endothelial growth factor (VEGF) is a very effective
factor in inducing the formation of new blood vessels, and acts
speciﬁcally on endothelial cells. VEGF is expected to play impor-
tant roles in inﬂammation and during normal and pathological
angiogenesis, a process that is associated with wound healing,
embryonic development, and growth and metastasis of solid
tumours (Brown et al, 1992; Collins et al, 1993). VEGF is a
homodimeric 34–42 kDa, heparin-binding glycoprotein and is
expressed by almost all human solid tumours (Senger et al,
1986).
Pleiotrophin (PTN) (Li et al, 1990), also referred to as hepar-
in-binding growth-associated molecule (HB-GAM) (Merenmies
and Rauvala, 1990), is a growth factor which is involved in
the differentiation and proliferation of neuronal cells during
embryogenesis (Merenmies and Rauvala, 1990; Bohlen and
Kovesdi, 1991). Pleiotrophin is a very basic protein of an appar-
ent mass of 18 kDa, which is differentially expressed during pre-
and postnatal development (Hampton et al, 1992). During
embryogenesis PTN is strongly expressed in brain, liver, spleen,
lung, bone and tongue. Only weak expression of PTN is found
in adult brain, liver, bone and tongue, with low to no expression
in other organs (Merenmies and Rauvala, 1990; Vanderwinden et
al, 1992).
Elevated PTN expression has been shown to occur in malig-
nant tumours with respect to normal tissue, for example in
ovarian carcinoma, and in tumour cell lines such as breast carci-
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1997). A recent study investigated PTN in the serum of patients
with various cancers and the results indicated that PTN is asso-
ciated with the presence of tumour (Souttou et al, 1998; Kuroi
and Toi, 2001).
We have previously shown that PTN mRNA is strongly
expressed in human lung cancer cell lines, particularly in those
cell lines derived from small cell lung cancer (Ja ¨ger et al, 1997).
In the present study we have evaluated the serum concentration
of PTN in patients with lung cancer in comparison with a control
group of healthy subjects, using a modiﬁed highly sensitive
enzyme-linked immunosorbent assay (Souttou et al, 1998).
Furthermore, we compared the serum concentration of PTN in
these patients with the plasma concentration of the classical
angiogenic growth factor, VEGF, with respect to disease staging
and response to therapy.
PATIENTS AND METHODS
Patients and healthy control subjects
Serum and plasma samples were obtained prospectively from
63 patients with histologically conﬁrmed small cell lung carci-
noma (SCLC) (University of Marburg, 52 males; median age
58 years). Twenty-three of the SCLC patients were staged as
very limited disease (VLD) or limited disease (LD) (the
tumour conﬁned to one hemithorax and regional lymph
nodes) and 40 patients were staged as extensive disease
(ED) (tumour occurrence beyond these regions). Patients with
extensive disease were subclassiﬁed into extensive I (no metas-
tasis outside the lung), and extensive II (metastasis outside
the lung) (EDI and EDII). Serum and Plasma samples were
also obtained from 22 patients with non-small cell lung
cancer (NSCLC) (median age 62 years; University of Marburg,
Germany), 12 of whom were staged as IIb/IIIA and 10 of
whom were staged as IIIB/IV. Forty-one healthy blood donors
(University of Marburg) provided serum samples for the
control group (25 male, median age 41 years).
Tumour specimens were obtained through biopsy by broncho-
scopy in ﬁve lung cancer patients. The specimens were frozen in
liquid nitrogen and stored at 7808C until analysis.
RNA preparation and RT–PCR
RNA was isolated from tumour specimens by the RNAzol
method (Cinna/Biotech, Houston, TX, USA). Brieﬂy, samples
were treated with 2 ml RNAzol and 200 ml chloroform, then
centrifuged for 15 min at 15000 r.p.m. The supernatant was
carefully removed and diluted with the same volume of
isopropanol. After centrifugation the pellet was washed twice
with 75% ethanol and resuspended in 50–100 ml of distilled
water.
Reverse transcription
Total RNA (1 mg/7.5 ml) was denaturated at 708C for
10 min. Denaturated RNA was reverse-transcribed in a
30 ml ﬁnal volume of 56RT buffer (10 mM Tris (pH 8.3),
50 mM KCl, 1.5 mM MgCl2), 625 m of each dNTP, 2.5
RNasin (Boehringer Mannheim, Germany), 10 mM dithiothrei-
tol and 5 U reverse transcriptase. The reaction mixture was
incubated for 1 h at 378C and stopped by an incubation
for 10 min at 908C.
PCR
The cDNA (1.5 ml) was ampliﬁed in a 30 ml ﬁnal volume of
10 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 200 ml of each
dNTP, 0.5 mM of each primer and 1.25 U Taq polymerase (Boeh-
ringer Mannheim, Germany) for 25–30 cycles under the
following conditions: 5 min at 958C, 1 min at 56.58C (PTN)
or at 588C (GAPDH) and 2 min at 738C. GAPDH was used
as a control. PCR products were loaded on a 1.5% ethidium
bromide-stained agarose gel. Primer sequences were as follows:
PTN, sense 5' GGT CTC GAG TAT GTT CCA CAG GTG
ACA TC 3' and anti-sense 5' GGT AAG CTT AGA GGA CGT
TTC CAA CTC AA 3'; GAPDH sense 5'CGT CTT CAC CAT
GGA GA 3' and anti-sense 5' GCC GGT AGT GCG GTG
TCA AA 3'.
Collection of blood samples, ELISA for PTN and VEGF
Blood samples were collected into EDTA-coated tubes and
stored at 48C overnight. Subsequently, samples were centrifuged
to isolate serum and plasma. Haemolytic or lipemic samples
were excluded. Aliquots of serum and plasma from each
subject were stored at 7808C. ELISA results were not inﬂu-
enced by the duration of storage at 7808C, which ranged
from 1 month to 4 years. The serum and plasma levels of
PTN were determined by using a highly sensitive enzyme-
linked immunosorbent assay as previously described (Souttou
et al, 1998). In brief, a mouse anti-PTN monoclonal antibody
(4B7) (Souttou et al, 1998) was diluted to 1 mgm l
71 in Tris-
buffered saline (TBS). Aliquots (100 ml) of the diluted antibody
were incubated in 96-well plates (Life Technologies, Germany)
at 48C overnight. Wells were washed three times with TBST
(50 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.5% Tween
20). Residual free binding sites were blocked with 200 ml TBST
containing 1% bovine serum albumin for 2 h at 48C, before
washing the wells three times with TBST. Serum was diluted
1:1 with double concentrated TBST. One hundred microlitres
of this dilution was added per well and incubated at room
temperature for 1 h. The wells were then washed three times
with TBST and the secondary antibody, a biotinylated afﬁ-
nity-puriﬁed anti-human PTN goat immunoglobin G (IgG)
(R&D, Germany), was added at a concentration of
500 ng ml
71 and incubated at room temperature for 1 h. After
washing three times with TBST, 100 ml of streptavidin-conju-
gated alkaline phosphatase (50 ng ml
71) was added per well
and incubated for 1 h at room temperature. The plate was
then washed three times with TBST and incubated with
100 ml of a p-nitrophenyl phosphate substrate in the dark at
room temperature for 2 h. Absorbance was measured with a
microtiter plate reader (Labsystems Multiscan, Frankfurt,
Germany) at 405 nm. Recombinant human pleiotrophin
(PTN) (R&D, Germany) served as control to provide a stan-
dard curve. Results were analysed using Genlite (Labsystems
Multiscan). SAS (Cary, NC, USA) software was used for the
statistical analysis.
In the second ELISA we used a human VEGF-immunoassay Kit
from Quantikine (R&D Systems, Germany). This assay employs
also the quantitative sandwich enzyme immunoassay technique.
Serum and plasma levels of VEGF were determined.
RESULTS
All samples were analysed for PTN and VEGF in serum and
plasma. Serum and plasma levels of PTN were comparable
(not shown). Therefore serum levels of PTN were used to
show the data, in order to keep up consistency with results
published previously (Souttou et al, 1998). Serum levels of
VEGF turned out to be about ﬁve times higher than plasma
levels. In order to avoid interference with VEGF released from
platelets, the data were demonstrated by showing VEGF plas-
ma levels. Therefore PTN serum levels were compared with
VEGF plasma levels.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(6), 858–863Detection of pleiotrophin in serum of patients with lung
cancer in comparison to healthy control subjects
In our study a group of 41 healthy blood donors 16 had pleio-
trophin serum concentrations below the sensitivity of the ELISA
assay. The maximum serum concentration measured in the
control group was 3230 pg ml
71 and the average concentration
was 830 pg ml
71. This is somewhat higher than a previous
study (Souttou et al, 1998), most likely due to modiﬁcations
of the ELISA assay and the collection and preparation of blood
samples.
In Figure 1 the serum concentrations of PTN in control
subjects and lung cancer patients are shown. Our results show
elevated serum levels in patients with SCLC and NSCLC with
respect to the controls (P50.001). In 97.6% of the healthy volun-
teers the serum concentrations of PTN were below 3000 pg ml
71.
We used this as an arbitrary cut-off value for elevated PTN serum
levels (43000 pg ml
71). Under these conditions, serum concen-
trations of PTN were elevated in 81% of all investigated lung
cancer patients, in 63% of NSCLC patients (P50.002) and in
87% of SCLC patients (P50.001). The mean PTN serum concen-
tration were 10.8-fold greater in the tumour patients relative to
controls.
Disease stage relative to serum concentrations of PTN
The mean serum PTN concentrations in SCLC patients with exten-
sive disease II (EDII) was 11431 pg ml
71 (n=26), EDI
9690 pg ml
71 (n=16), limited disease (LD) 7068 pg ml
71 (n=20)
and in one patient with very limited disease (VLD) 814 pg ml
71
(n=1) (Figure 2A). Statistical analysis showed a signiﬁcant positive
correlation between serum PTN concentration and stage of disease
in SCLC patients.
Similarly, the serum concentration of PTN was found to
increase with the disease stage of NSCLC patients. The mean serum
PTN concentration was 6909 pg ml
71 (n=10) in patients with
tumour stage IIB/IIIA and 19944 pg ml
71 (n=12) in patients with
tumour stage IIIB/IV (Figure 2B). Patients with PTN serum levels
above the median showed a median overall survival of 10 months.
Survival of patients with PTN serum levels below the median
ranged from 14 months to 42 years up to now (data not shown).
Some of these patients are still alive at the present date. Due to the
small number of patients statistical analysis did not reveal a signif-
icant difference.
PTN serum concentration in patients relative to therapy
The serum concentration of PTN was monitored in seven patients
from the time of diagnosis over the course of two cycles of
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Figure 1 Serum concentrations of PTN. The numbers in brackets show
the portion above and below the cut-off set as the highest value in the
control group.
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Figure 2 PTN serum concentrations according to stage of disease in
patients with SCLC (A) and NSCLC (B).
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the second cycle (Figure 3). Two patients entered remission after
one cycle of treatment. In these patients the PTN serum concentra-
tion decreased after both chemotherapy cycles. Three patients
showed little clinical response to the ﬁrst chemotherapy course,
with progression of disease by the end of the second cycle. In these
cases the serum PTN concentration either remained stable or rose
further. Two patients showed partial remission but relapsed after
the second cycle. Both patients showed an initial decrease in serum
PTN concentration but a subsequent increase coincident with the
relapse.
Detection of VEGF in plasma of patients with lung cancer
In parallel with the measurements of PTN, we investigated the
plasma concentration of VEGF in the same group of patients with
lung cancer compared to control subjects (Figure 4). The mean
plasma VEGF concentration in the group of control subjects
was 40 pg ml
71 compared to 91 pg ml
71 in the group of lung
cancer patients (154 pg ml
71 in the NSCLC group and
69 pg ml
71 in the SCLC group), constituting a 2.3-fold higher
concentration of VEGF in lung cancer patients overall. 45.5% of
NSCLC patients and 28.6% of SCLC patients were above the
cut-off value of 65 pg ml
71 established from the study in control
subjects. No correlation between VEGF plasma concentration and
histological diagnosis or stage of disease was found (data not
shown).
Comparison of PTN and VEGF expression in patients with
SCLC and NSCLC
Since VEGF is a classical marker of angiogenesis, known to be
elevated within the plasma of the majority of cancer patients, we
have used it in our study for comparison with PTN. The serum
PTN concentrations in each of the patients studied bore no corre-
lation with the VEGF plasma concentrations (not shown).
Expression of PTN mRNA in lung cancer specimens
The expression of PTN transcripts was determined in tumour
specimens obtained from ﬁve lung cancer patients. RT–PCR
analysis revealed that all tumour specimens investigated expressed
PTN-mRNA (Figure 5).
DISCUSSION
Since PTN is expressed by endocrine cells (Riegel and Well-
stein, 1994), we were interested to investigate whether its
expression is a feature of the neuroendocrine tumour SCLC
and whether it can be detected within the serum of patients
with this tumour. We have previously shown that in lung
cancer cell lines PTN mRNA is predominantly expressed in
78% of SCLC cell lines compared to only 25% of NSCLC
cell lines (Ja ¨ger et al, 1997).
The aim of the present study was to investigate in a prospective
trial the potential merit of measuring concentrations of PTN in
patients with lung cancer, by evaluating the distribution of this
recently described angiogenic factor in comparison to that of the
classical angiogenic growth factor, VEGF.
Our results reveal a distribution of elevated PTN serum levels in
lung cancer patients that closely resembles the distribution of PTN
expression in lung cancer cell lines (Ja ¨ger et al, 1997). Although the
mean serum PTN concentration measured was greater in NSCLC
than SCLC patients, it was elevated with respect to control subjects
in a smaller portion of patients (63% of NSCLC vs 87% of SCLC
patients). Since the age and sex ratios of the control subject group
differed from the patient group, we age- and sex-matched 10
subjects from each of these two groups and found that neither
age nor sex bore any inﬂuence on the serum PTN concentration
(data not shown). These results suggest that PTN, as measured
in serum by ELISA, may be a valuable marker of lung cancer,
and in particular SCLC. Furthermore, the functional signiﬁcance
of PTN as a potent angiogenic factor in lung cancer clearly merits
further investigation.
To our knowledge only one other study has reported elevated
serum PTN concentrations in patients to date (Souttou et al,
1998). Souttou et al (1998) found signiﬁcantly elevated PTN levels
in patients with pancreatic carcinoma (n=41; P50.0001) and
colon cancer (n=65; P50.0079) in comparison to 28 control
subjects. Clearly, PTN has potential to serve as a marker of the
presence of malignant disease, although it is unlikely to differenti-
ate between tumour types. PTN overexpression in breast cancer
cells induces increased vascular density in vivo, implicating an
angiogenic role (Choudhuri et al, 1997). In primary human breast
cancer, pleiotrophin expression is correlated with acidic FGF
expression as demonstrated by Rnase protection analysis. Midkine
a heparin-binding growth factor, which has a 45% sequence
homology to PTN, shows a signiﬁcant elevation of serum level
in patients with various carcinomas (Relf et al, 1997; Ikematsu
et al, 2000).
C
l
i
n
i
c
a
l
12 3 45
PTN –
GAPDH –
– 540 bp
– 330 bp
Figure 5 Pleitrophin (PTN) mRNA expression in tumour specimens of
three small-cell-lung cancer (SCLC, lanes 1, 3 and 5) patients and two non-
small cell lung cancer (NSCLC, lanes 2 and 4) patients as determined by
RT–PCR (for details see Patients and Methods).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(6), 858–863In addition to the clinically relevant ﬁnding that PTN is detect-
able in the serum of tumour patients, it is important to ascertain
whether the source of PTN production is the tumour itself. Our
result, that the serum PTN concentration in lung cancer patients
correlates positively with the stage of disease, supports the hypoth-
esis that PTN is produced by the tumour tissue. This hypothesis is
further supported by our ﬁnding of PTN-mRNA expression in lung
cancer specimens.
Finally, the serial measurements of serum PTN in seven
patients undergoing chemotherapy showed signiﬁcant reductions
in PTN concentrations in those patients who responded clinically
to treatment, but in none of those patients in whom disease
progressed. In these latter patients PTN serum concentrations rose
or remained constant. Similarly, Souttou et al (1998) found
evidence of direct PTN secretion by tumour tissue. After the
growth of implanted human PTN-expressing tumour cells within
PTN-negative mice, PTN became detectable in the serum of the
mice. Furthermore, after operative removal of the tumours the
serum PTN concentrations in the mice returned to undetectable
levels. The same results have been found in patients, when
successful removal of pancreatic tumours led to a reduction in
PTN serum levels (Souttou et al, 1998). Our data might give a
preliminary indication for a longer survival of lung cancer patients
with lower PTN serum levels as compared to the survival of lung
cancer patients with higher PTN serum levels (not shown).
However, larger studies are necessary to address this issue for a
deﬁnite conclusion.
In the ﬁnal section of our study, the plasma concentrations of
VEGF were analysed for the same lung cancer patient and control
groups to obtain a direct comparison with the data for PTN. A
number of studies investigating VEGF serum levels in lung cancer
patients have shown that the expression of VEGF does not corre-
late with either the histological type or the grade of lung cancer
(Brattstrom et al, 1998; Takigawa et al, 1998) and our results are
in agreement with these studies. Clearly, despite its potent angio-
genic properties and acknowledged role as a marker of poor
prognosis in various other malignant conditions (Nguyen, 1997),
VEGF has only a limited role as a prognostic marker of lung
cancer. In contrast, we show here that the measurement of serum
PTN concentration may offer an effective marker of lung cancer,
particularly of SCLC, with the possibility to monitor the response
to therapy.
In conclusion our results indicate that PTN might be a prognos-
tic factor for lung cancer and larger prospective further studies are
required to conﬁrm this hypothesis.
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